Dean, Provost & Exe. Deputy Chancellor UMass School of Medicine
Terence R. Flotte, MD, is dean of the School of Medicine and provost & executive deputy chancellor of the University of Massachusetts Medical School (UMMS). In these roles, Dr. Flotte serves UMMS as chief academic and administrative officer of the School of Medicine, overseeing all academic activities of the basic and clinical science departments, including education and research for the School of Medicine and the Graduate School of Biomedical Sciences.
Flotte joined the Medical School in May 2007 from the University of Florida, where he was the Nemours Eminent Scholar and Chair of the Department of Pediatrics for the College of Medicine. Flotte received his undergraduate degree in the biological sciences from the University of New Orleans in 1982, and his medical degree from the Louisiana State University School of Medicine in 1986. After serving his residency in pediatrics at Johns Hopkins University, he completed a pediatric pulmonary fellowship and postdoctoral training in molecular virology there in 1992.
In 1996, Flotte joined the faculty of the University of Florida and was appointed Associate Director of UF's Powell Gene Therapy Center. In 2000, he was named Director of the Powell Center and founding Director of the newly established UF Genetics Institute, a cross-campus multidisciplinary unit encompassing gene therapy, human genetics, agricultural genetics and comparative genomics. In 2002, Flotte stepped down from these roles to accept the position of Chair of the Department of Pediatrics.
As UF Pediatrics Chair, Flotte led the department in a number of key projects, including the establishment of a Division of Cellular and Molecular Therapy that has garnered more than $2 million per year in extramural funding from the National Institutes of Health and the creation of the Congenital Heart Disease Center of Excellence, which combines cutting-edge clinical care from pediatric cardiac surgery and cardiology in a unique single-line-of-business entity. Under his stewardship, the research grant revenue to the Department of Pediatrics nearly doubled and clinical revenue increased by nearly 50 percent. Key faculty recruits and high productivity in critical strategic areas, such as translational research in regenerative medicine and vital clinical programs in congenital heart disease, neurology and hematology-oncology, also characterized Flotte's successful UF tenure.
An internationally known pioneer in human gene therapy, Flotte is currently investigating the use of gene therapy for genetic diseases that affect children, mainly cystic fibrosis. In 1995, Flotte and his colleagues at Johns Hopkins became the first to use the apparently harmless adeno-associated virus, or AAV, as a vehicle to deliver corrective genes to targeted sites in the body, including the damaged airways of adults with cystic fibrosis. Since joining UF, Flotte has continued his pediatric practice while pursuing clinical trials and basic laboratory research to determine how to treat genetic disorders using vectors, or viruses modified to carry corrective genes. He is the author of more than 130 scholarly papers and his research has been funded by the National Institutes of Health, the Cystic Fibrosis Foundation and the Juvenile Diabetes Research Foundation.
Flotte has received numerous honors and awards including the Society for Pediatric Research's E. Mead Johnson Award for Outstanding Scientific Contributions and the University of Florida Faculty Research Prize in Clinical Science. He is a member of the American Society for Gene Therapy and the American Society of Microbiology, among many other professional associations.